Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OptiScan Biomedical Corp.

www.optiscancorp.com

Latest From OptiScan Biomedical Corp.

US Approvals Analysis: Original PMA Slowdown, De Novo Upswing Among Recent Trends

The volume of original PMAs coming to US FDA for review is down recently, while panel-track supplement, de novo and 510(k) volumes are up. October, meanwhile, was a relatively light month for novel device approvals, but better-than-average for 510(k) clearances.

Approvals Innovation

Tight Glycemic Control: Critical Care’s Balancing Act

Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.

Medical Device

Tight Glycemic Control: Critical Care’s Balancing Act

Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving outcomes. Today, GlySure and others are working on continuous glucose monitoring for the critical care environment to help deliver on that promise.

Medical Device

GlySure Ltd.

Despite mounting evidence that controlling blood sugar levels in critical care patients reduces complications and shortens the length of ICU stay, clinicians have found total glucose control hard to achieve because of the frequent testing required to achieve tight management. GlySure Ltd. is developing a continuous intravascular glucose monitoring system based on optical fluorescence. The start-up says that its sensor, inserted into the patient through central venous or arterial lines, can be used to monitor glucose and other parameters continuously for long periods of time without clotting or other adverse effects.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OptiScan Biomedical Corp.
  • Senior Management
  • Peter Rule, CEO
    Patrick Nugent, CFO
    Donald Webber, COO
  • Contact Info
  • OptiScan Biomedical Corp.
    Phone: (510) 342-5800
    21021 Corsair Blvd.
    Suite 101
    Hayward, CA 94545
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register